Summary
We reviewed our experience for adult patients receiving oral anticonvulsant therapy during high-dose chemotherapy and autologous bone marrow re-infusion for primary malignant tumors of the central nervous system. Nineteen patients received either iv carmustine (BCNU) 900–1050 mg/m2 and 6120 cGy cranial irradiation (N = 10), iv carmustine 900–1050 mg/m2 and iv cisplatin 200 mg/m2 (N = 8), or iv carmustine 600 mg/m2, iv cisplatin 200 mg/m2, and iv etoposide 2400 mg/m2 (N = 1). Anticonvulsant therapy consisted of phenytoin alone (N = 8), phenobarbital alone (N = 4), carbamazepine alone (N = 2), phenytoin and carbamazepine (N = 2), carbamazepine and phenobarbital (N = 1), and no anticonvulsant therapy (N = 2). Serum anticonvulsant concentrations were monitored frequently and doses adjusted to keep values in the therapeutic range. While phenobarbital and carbamazepine doses remained relatively stable, all patients required increased doses of phenytoin anticonvulsant therapy after beginning chemotherapy (mean onset 3.7 days after initiation of chemotherapy). The increase in phenytoin dose ranged from 50% to 300% above baseline (mean 134%). By the time of discharge from the hospital (approximately 3–4 weeks after the start of chemotherapy) anticonvulsant dose was decreased to near pre-therapy levels. These swings coincided with the initiation of dexamethasone therapy for antiemetic effect and were more pronounced in patients also receiving cisplatin therapy. Due to close monitoring of serum phenytoin concentrations, no instances of toxicity due to excessive drug concentration, or seizures due to subtherapeutic doses, were noted in patients with primary CNS malignancies. Serum phenytoin concentrations fluctuate markedly during high-dose chemotherapy and must be analyzed frequently during the course of therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Kelly KA, Kirkwood JM, Kapp DS: Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Review 11: 1–26, 1984
Cooper JS, Borok TL, Ransohoff J, Carella RJ: Malignant glioma. Results of combined modality treatment. J Am Med Assoc 248: 62–65, 1982
Walker MD, Green SB, Byar DP, et al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323–1329, 1980
Green SB, Byar DP, Walker MD, et al.: Comparisons of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121–132, 1983
Eagan RT, Scott M: Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol 1: 38–44, 1983
Levin VA: Pharmacokinetics and CNS chemotherapy. In: Hellmann K, Carlese SA (eds) Fundamentals of Cancer Chemotherapy. McGraw-Hill, New York, P. 28, 1986
Levin VA: Chemotherapy of primary brain tumors. Neurologic Clin 3: 855–866, 1985
Edwards MS, Levin VA, Wilson CB: Brain tumor chemotherapy: An evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64: 1179–1205, 1980
Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of commonly used anti-neoplastic agents. N Engl J Med 291: 75–81, 1974
Stewart DJ, Leavens M, Maor M, et al.: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474–2479, 1982
Ciobanu N, Dutcher J, Gucalp R, et al.: High dose chemotherapy with autologous bone marrow transplantation (ABMT) for malignant melanoma after failure of interleukin-2 (IL-2) and lymphokine activated killer (LAK) cells. (Abstr.) Proc Am Soc Clin Oncol 8: 281, 1989
Johnson DB, Thompson JM, Corwin JA, et al.: Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. J Clin Oncol 5: 783–789, 1987
Green SB, Byar DB, Strike TA, et al.: Randomized comparison of single or multiple drug chemotherapy combined with either whole brain or whole brain plus coned-down boost radiotherapy for the post-operative treatment of malignant glioma (Study 8001). (Abstr.) Proc Am Soc Clin Oncol 5: 135, 1986
Lazarus H, Crilley P, Ciobanu N, et al.: High-dose BCNU, cisplatin, VP-16 with or without involved field radiotherapy (AFRT) and autologous bone marrow transplantation (AUBMT) for relapsed or refractory lymphoma (abstr.). Blood 74: 165a, 1989
Cassileth PA, Lusk EJ, Torri S, et al.: Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Ann Intern Med 143: 1347–1349, 1983
Jusko W, Koop J, Alvan G: Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm 4: 327–336, 1976
Eadie MJ: Anticonvulsant drugs: an update. Drugs 27: 338–363,1984
Perucca E: Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 7: 57–84, 1982
Warren RD, Bender AR: Drug interactions with antineoplastic agents. Cancer Treat Rep 61: 1231–1241, 1977
Teunissen MWE, Willemse PHB, Sleijfer DT, et al.: Antipyrine metabolism in patients with disseminated testicular cancer and the influence of cytostatic treatment. Cancer Chemother Pharmacol 13: 181–185, 1984
Guengerich FP: Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 48: 2946–2954, 1988
Wong DD, Longnecker RG, Liepman M, Baker S, La Vergne M: Phenytoin-dexamethasone: A potential drug interaction (letter). J Am Med Assoc 254: 2062–2063, 1985
Finchum RW, Schottelius DD: Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit 1: 277–283, 1979
Bollini P, Riva R, Albani F, et al.: Decreased phenytoin levels during antineoplastic therapy: a case report. Epilepsia 24: 75–78, 1983
Sylvester RK, Lewis FB, Caldwell KC, et al.: Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine and bleomycin. Ther Drug Monit 6: 302–305, 1984
Jarosinski PF, Moslow JA, Alexander MS, et al.: Altered phenytoin clearance during intensive treatment for acute lymphoblastic leukemia. J Pediatr 112: 996–999, 1988
Neef C, Voogd-van der Straaten I: An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 43: 372–375, 1988
Grossman SA, Sheilder VR, Gilbert MR: Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 87: 505–510, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ghosh, C., Lazarus, H.M., Hewlett, J.S. et al. Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors. J Neuro-Oncol 12, 25–32 (1992). https://doi.org/10.1007/BF00172454
Issue Date:
DOI: https://doi.org/10.1007/BF00172454